ArticleImmunity, inflammation and disease2026
Predictive Role of Serum Inflammatory Markers in Metastatic Luminal A/B Breast Cancers Receiving CDK-4/6 Inhibitors Therapy.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe conducted this study to evaluate the impact of serum inflammatory markers and histopathological features on prognosis in metastatic hormone receptor positive breast cancer patients treated with first line CDK4/6i (cyclin-dependent kinase inhibitors).
objectivesWhile serum markers are better indicators in triple-negative and HER-2 positive breast cancers, the PFS (progression-free survival) durations of NLR (neutrophil/lymphocyte ratio), PLR (platelet/lymphocyte ratio), and LMR (platelet/lymphocyte ratios) in luminal A-B group patients vary between studies. In our study investigated whether baseline NLR, PLR, and LMR have a predictive value for PFS in hormone-positive metastatic breast cancer receiving CDK4/6i. MATERIAL AND
methodsThe study included 111 patients with de novo metastasis or recurrence/metastasis after adjuvant/neo-adjuvant treatment who received CDK-4/6i as first-line therapy. NLR, PLR, LMR, lymphocyte, neutrophil, and monocyte values were recorded from peripheral blood analyses before CDK-4/6i treatment.
resultsWhen the patient characteristics of patients were analyzed for progression-free survival, no statistically significant differences were found between age, ECOG, grade, Ki-67 index, and menopause status. PFS was not significantly associated with NLR, PLR, and LMR values (p = 0.87, p = 0.51, p = 0.22, respectively. In univariate analysis, among patients with LMR > 3.48, ribociclib was associated with longer PFS than palbociclib. Multivariate analysis revealed that the luminal B molecular subtype was associated with significantly worse PFS compared to luminal A (23 vs. 43 months, respectively, p = 0.01).
conclusionsThe prognostic impact of serum inflammatory markers in hormone receptor-positive metastatic breast cancer is heterogeneous. Although no statistical significance was observed in our cohort, high LMR levels may provide predictive and prognostic value in treatment selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.